Pharmaron Beijing (China) Performance
| 300759 Stock | 26.95 0.23 0.86% |
On a scale of 0 to 100, Pharmaron Beijing holds a performance score of 10. The company holds a Beta of 0.79, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pharmaron Beijing's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharmaron Beijing is expected to be smaller as well. Please check Pharmaron Beijing's market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to make a quick decision on whether Pharmaron Beijing's historical price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Pharmaron Beijing Co are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Pharmaron Beijing sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0064 | Payout Ratio 0.1882 | Last Split Factor 1.5:1 | Forward Dividend Rate 0.2 | Ex Dividend Date 2024-06-27 |
1 | Pharmaron Beijing Sets EGM Shareholder Record Date - TipRanks | 08/26/2024 |
2 | Pharmaron Beijings 2024 Q3 Financial Report Unveiled - TipRanks | 10/29/2024 |
| Begin Period Cash Flow | 1.4 B | |
| Free Cash Flow | -111.8 M |
Pharmaron |
Pharmaron Beijing Relative Risk vs. Return Landscape
If you would invest 1,968 in Pharmaron Beijing Co on August 28, 2024 and sell it today you would earn a total of 727.00 from holding Pharmaron Beijing Co or generate 36.94% return on investment over 90 days. Pharmaron Beijing Co is generating 0.6923% of daily returns and assumes 5.4518% volatility on return distribution over the 90 days horizon. Simply put, 48% of stocks are less volatile than Pharmaron, and 87% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pharmaron Beijing Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmaron Beijing's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharmaron Beijing Co, and traders can use it to determine the average amount a Pharmaron Beijing's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 300759 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.45 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.69 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Pharmaron Beijing is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmaron Beijing by adding it to a well-diversified portfolio.
Pharmaron Beijing Fundamentals Growth
Pharmaron Stock prices reflect investors' perceptions of the future prospects and financial health of Pharmaron Beijing, and Pharmaron Beijing fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmaron Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 46.66 B | ||||
| Shares Outstanding | 1.49 B | ||||
| Price To Book | 3.57 X | ||||
| Price To Sales | 3.99 X | ||||
| Revenue | 11.54 B | ||||
| Gross Profit | 2.68 B | ||||
| EBITDA | 2.39 B | ||||
| Net Income | 1.6 B | ||||
| Total Debt | 577.07 M | ||||
| Book Value Per Share | 7.57 X | ||||
| Cash Flow From Operations | 2.75 B | ||||
| Earnings Per Share | 1.06 X | ||||
| Total Asset | 26.48 B | ||||
| Retained Earnings | 5.2 B | ||||
About Pharmaron Beijing Performance
By analyzing Pharmaron Beijing's fundamental ratios, stakeholders can gain valuable insights into Pharmaron Beijing's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharmaron Beijing has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmaron Beijing has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharmaron Beijing is entity of China. It is traded as Stock on SHE exchange.Things to note about Pharmaron Beijing performance evaluation
Checking the ongoing alerts about Pharmaron Beijing for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharmaron Beijing help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmaron Beijing is way too risky over 90 days horizon | |
| Pharmaron Beijing appears to be risky and price may revert if volatility continues | |
| About 42.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Pharmaron Beijings 2024 Q3 Financial Report Unveiled - TipRanks |
- Analyzing Pharmaron Beijing's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmaron Beijing's stock is overvalued or undervalued compared to its peers.
- Examining Pharmaron Beijing's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmaron Beijing's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmaron Beijing's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmaron Beijing's stock. These opinions can provide insight into Pharmaron Beijing's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharmaron Stock analysis
When running Pharmaron Beijing's price analysis, check to measure Pharmaron Beijing's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmaron Beijing is operating at the current time. Most of Pharmaron Beijing's value examination focuses on studying past and present price action to predict the probability of Pharmaron Beijing's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmaron Beijing's price. Additionally, you may evaluate how the addition of Pharmaron Beijing to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |